SEELOS THERAPEUTICS, INC.: Nasdaq/NYSE listing notice — Seelos receives Nasdaq notices for bid price and market value non-compliance

SEELOS THERAPEUTICS, INC.

Bid price below $1.00 for 30 consecutive days; compliance deadline April 29, 2024.
Market value of listed securities below $35M for 32 consecutive days; deadline April 30, 2024.
Company may effect a reverse stock split to cure deficiencies; no immediate trading impact.
Failure to comply may lead to delisting; company may appeal Nasdaq's determination.
Stock continues trading on Nasdaq Capital Market under symbol SEEL.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

SEELOS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

ith the First Notice, the “Notices”) from Nasdaq indicating that, for the last thirty-two consecutive business days, the market value of the Company’s listed securities has been below the minimum requirement of $35 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (“Rule 5550(b)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a period of 180 calendar days, or until April 30, 2024, to regain compliance. The Second Notice states that the Nasdaq staff will provide written notification that the Company has achi

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

SEELOS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 1, 2023, Seelos Therapeutics, Inc. (the “Company”) received written notice (the “First Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until April 29, 2024, to regain compliance. The F

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-114286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.